摘要
目的:探讨糖皮质激素鼻喷雾剂治疗过敏性鼻炎(AR)的临床疗效。方法:选取2020年5月—2022年5月本院就诊的AR患者160例作为研究对象,按照随机数字表法将其分为观察组(n=80)和对照组(n=80)。对照组采取地氯雷他定进行治疗,观察组则在对照组基础上联合糖皮质激素鼻喷雾剂治疗,比较两组临床疗效、炎症因子[白介素-6(IL-6)、白介素-10(IL-10)、肿瘤坏死因子α(TNF-α)]及预后情况(并发症发生率及复发率)。结果:观察组治疗总有效率为93.75%,高于对照组的83.75%(P<0.05);治疗后,观察组IL-6、TNF-α水平低于对照组,IL-10水平高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);随访3个月后,观察组复发率低于对照组(P<0.05)。结论:AR患者采取糖皮质激素鼻喷雾剂联合治疗方案的效果较好,可缓解患者临床症状,降低机体炎性因子水平,提升其治疗效果,值得临床应用。
Objective: To investigate the clinical efficacy of glucocorticoid nasal spray in the treatment of allergic rhinitis(AR). Methods: A total of 160 AR patients who were treated in our hospital from May 2020 to May 2022 were selected as the research objects. They were divided into observation group(n=80) and control group(n=80) according to the random number table method. The control group was treated with desloratadine, while the observation group was treated with glucocorticoid nasal spray on the basis of the control group. The clinical efficacy, inflammatory factors [interleukin-6(IL-6), interleukin-10(IL-10), tumor necrosis factor-α(TNF-α)] and prognosis(complication rate and recurrence rate) were compared between the two groups. Results: The total effective rate in observation group was 93.75%, which was higher than 83.75% in control group(P<0.05). After treatment, the levels of IL-6 and TNF-α in the observation group were lower than those in the control group, and the level of IL-10 was higher than that in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). After 3 months of follow-up, the recurrence rate of the observation group was lower than that of the control group(P<0.05).Conclusion: The combined treatment of glucocorticoid nasal spray in AR patients has a good effect, which can alleviate the clinical symptoms of patients, reduce the level of inflammatory factors in the body, and improve the therapeutic effect. It is worthy of clinical application.
作者
杨翠娥
涂海螺
石铁钢
YANG Cui'e;TU Hailuo;SHI Tiegang(Department of Otolaryngology,the Second Hospital of Integrated Traditional Chinese and Western Medicine,Nanchang 330006,Jiangxi,China;Department of Otolaryngology,Xinjian District People's Hospital,Nanchang 330199,Jiangxi,China;Department of Otology,Boda Otolaryngology Hospital,Jiangxi Academy of Medical Sciences,Nanchang 330001,Jiangxi,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第12期1848-1850,1858,共4页
Chinese Journal of Drug Abuse Prevention and Treatment